Lista de obras - Afschin Gandjour - Dominio Público Uruguay

A 'centres of excellence' approach in health care: points for and against

artículo científico publicado en 2002

A model to optimize investments in health technologies, quality of care and research

article

A model to predict the cost-effectiveness of disease management programs

artículo científico publicado en 2010

A model to transfer trial-based pharmacoeconomic analyses to clinical practice

artículo científico publicado en 2011

A national hypertension treatment program in Germany and its estimated impact on costs, life expectancy, and cost-effectiveness

artículo científico publicado en 2007

A new prize system for drug innovation

artículo científico publicado en 2011

A payer's perspective on the cost effectiveness of gastric bypass surgery

artículo científico publicado en 2009

A proportional rule for setting reimbursement prices of new drugs and its mathematical consistency

scientific article published on 23 March 2020

A simulation model to estimate cost-offsets for a disease-management program for chronic kidney disease

artículo científico publicado en 2014

A theoretical and empirical investigation into the willingness-to-pay function for new innovative drugs by Germany's health technology assessment agency (IQWiG).

artículo científico publicado en 2013

Accounting for increased non-target-disease-specific mortality in decision-analytic screening models for economic evaluation.

artículo científico publicado en 2012

Aging diseases - do they prevent preventive health care from saving costs?

article

An evidence-based disease-management program for patients with diabetic nephropathy.

artículo científico publicado en 2003

An evidence-based evaluation of quality and efficiency indicators

artículo científico publicado en 2002

Applying GRADE Criteria to Clinical Inputs to Cost-Effectiveness Modeling Studies

artículo científico publicado en 2018

Appropriateness of invasive cardiovascular interventions in German hospitals (2000–2001): an evaluation using the RAND appropriateness criteria ⬇️

artículo científico publicado el 1 de octubre de 2003

Assessing the value of a future study

artículo científico publicado en 2008

At what time is a reduction of medical under- or overtreatment sensible? Treatment of acute depression as an example

artículo científico publicado en 2004

Autonomy, Coercion, and Public Healthcare Guarantees: The Uptake of Sofosbuvir in Germany

artículo científico publicado en 2021

Avoiding research waste through cost-effectiveness analysis: the example of medication adherence-enhancing interventions

artículo científico publicado en 2014

Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe.

artículo científico publicado en 2014

Budgetary Impact and Cost Drivers of Drugs for Rare and Ultrarare Diseases

scientific article published on 27 November 2017

Burden-of-disease estimates

artículo científico publicado en 2003

Capturing disutility from waiting time

artículo científico publicado en 2014

Caregiversʼ Quality of Life and Economic Evaluations

artículo científico publicado el 1 de septiembre de 2012

Changing the organization of health care

Comment on "Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany".

artículo científico publicado en 2018

Comment on: "Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines"

artículo científico publicado en 2014

Comment on: "Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation".

artículo científico publicado en 2017

Comment on: "Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy"

artículo científico publicado en 2015

Comment on: "The Cost Effectiveness of High-Dose Versus Conventional Haemodialysis: A Systematic Review"

artículo científico publicado en 2016

Comment on: "The Role of Chronic Disease, Obesity, and Improved Treatment and Detection in Accounting for the Rise in Healthcare Spending Between 1987 and 2011".

artículo científico publicado en 2016

Comment on: "impact and cost-effectiveness of a universal strategy to promote physical activity in primary care".

artículo científico publicado en 2015

Commentary to: Cost of poor adherence to anti-hypertensive therapy in five European countries

artículo científico publicado en 2015

Comparing the validity of different measures of illness severity: a hospital-level analysis for acute myocardial infarction

artículo científico publicado en 2012

Considering productivity loss in cost-effectiveness analysis: a new approach

scientific article published on 01 November 2014

Consumption costs and earnings during added years of life - a reply to Nyman

scientific article published on 01 March 2006

Convergence of decision rules for value-based pricing of new innovative drugs.

artículo científico publicado en 2014

Cost Effectiveness of Secondary vs Tertiary Prevention for Post-Menopausal Osteoporosis

artículo científico publicado el 1 de julio de 2011

Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany

scientific article published on 01 February 2020

Cost effectiveness of the German screen-and-treat strategy for postmenopausal osteoporosis

artículo científico publicado en 2008

Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women

artículo científico publicado en 2008

Cost-Effectiveness Analysis of High-Efficiency Hemodiafiltration Versus Low-Flux Hemodialysis Based on the Canadian Arm of the CONTRAST Study

artículo científico publicado en 2015

Cost-Effectiveness of Different Strategies for Selecting and Treating Individuals at Increased Risk of Osteoporosis or Osteopenia: A Systematic Review ⬇️

artículo científico publicado el 2 de febrero de 2012

Cost-effectiveness analysis of different screening procedures for type 2 diabetes: the KORA Survey 2000.

artículo científico publicado en 2004

Cost-effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in newly diagnosed type 2 diabetes in Germany

artículo científico publicado en 2010

Cost-effectiveness of angiotensin-converting enzyme inhibitors for the prevention of diabetic nephropathy in The Netherlands--a Markov model

artículo científico publicado en 2011

Cost-effectiveness of angiotensin-converting enzyme inhibitors in nondiabetic advanced renal disease.

artículo científico publicado en 2011

Cost-effectiveness of cardioverter-defibrillators in heart failure patients

artículo científico publicado en 2009

Cost-effectiveness of future lockdown policies against the COVID-19 pandemic

artículo científico publicado en 2022

Cost-effectiveness of implantable defibrillators after myocardial infarction based on 8-year follow-up data (MADIT II).

artículo científico publicado en 2011

Cost-effectiveness of preventing hip fractures by hip protectors in elderly institutionalized residents in Germany

artículo científico publicado en 2008

Cost-effectiveness of preventing weight gain and obesity: what we know and what we need to know

artículo científico

Cost-effectiveness of referrals to high-volume hospitals: an analysis based on a probabilistic Markov model for hip fracture surgeries

artículo científico publicado en 2006

Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results

scientific article published on 02 October 2020

Cost-effectiveness of using clinical risk factors with and without DXA for osteoporosis screening in postmenopausal women

artículo científico publicado en 2009

Costs and quality in the treatment of acute depression in primary care: a comparison between England, Germany and Switzerland

scientific article published on 01 July 2004

Costs of dialysis--a regional population-based analysis

artículo científico publicado en 2009

Costs of patients with chronic kidney disease in Germany

scientific article published on 24 April 2020

Defining Comparators According to IQWiG's Efficiency-Frontier Method

artículo científico publicado en 2020

Depression and health-related quality of life.

artículo científico publicado en 2003

Determining the price for pharmaceuticals in Germany: comparing a shortcut for IQWiG's efficiency frontier method with the price set by the manufacturer for ticagrelor

artículo científico publicado en 2013

Direct costs of care in germany for children and adolescents with diabetes mellitus in the early course after onset

artículo científico publicado en 2004

Does prevention save costs?

scientific article published on 20 March 2005

Drug pricing and control of health expenditures: a comparison between a proportional decision rule and a cost-per-QALY rule

artículo científico publicado en 2014

Economic analysis of influenza vaccination and treatment

Economic evaluation of Sinfrontal in the treatment of acute maxillary sinusitis in adults

artículo científico publicado en 2009

Economic evaluations alongside equivalence and noninferiority trials

artículo científico publicado en 2009

Educating authors and reviewers of economic evaluations of health care

scientific article published on 01 August 2002

Educational epidemiology

Empirical validation of patient versus population preferences in calculating QALYs

artículo científico publicado en 2011

Ethical criteria for allocating health-care resources

artículo científico publicado en 2009

Ethical objections against including life-extension costs in cost-effectiveness analysis: a consistent approach

artículo científico publicado en 2014

European comparison of costs and quality in the treatment of acute back pain

artículo científico publicado en 2005

Germany's decision rule for setting ceiling prices of drugs: a comparative analysis with other decision rules

artículo científico publicado en 2011

Health care expenditures from living longer--how much do they matter

artículo científico publicado en 2013

How much does it cost to change the behavior of health professionals? A mathematical model and an application to academic detailing

artículo científico publicado en 2005

Impact of demographic changes on healthcare expenditures and funding in the EU.

artículo científico publicado en 2005

Impact of small study bias on cost-effectiveness acceptability curves and value of information analyses

artículo científico publicado en 2014

Improving communication of health-related quality of life

artículo científico publicado en 2003

Incorporating feelings related to the uncertainty about future health in utility measurement

artículo científico publicado en 2008

Inductive reasoning in medicine: lessons from Carl Gustav Hempel's 'inductive-statistical' model.

artículo científico publicado en 2003

Informing patients of their coronary risk

artículo científico publicado en 2008

Internal validation of models with several interventions

artículo científico publicado en 2012

Investment in quality improvement: how to maximize the return

artículo científico publicado en 2010

Limiting Free Pricing of New Innovative Drugs After Launch: A Necessity for Payers?

artículo científico publicado en 2016

Loss aversion and cost effectiveness of healthcare programmes

artículo científico publicado en 2008

Modifiable behavioral factors as causes of death

scientific article published on 01 June 2004

Osteoporosis in German men: a cost-of-illness study

artículo científico publicado en 2014

Patient preferences: a Trojan horse for evidence-based medicine?

artículo científico publicado en 2018

Pharmaceutical expenditure and gross domestic product: Evidence of simultaneous effects using a two-step instrumental variables strategy

artículo científico publicado en 2018

Pharmaceutical risk-sharing agreements

artículo científico publicado en 2009

Predictors of negotiated prices for new drugs in Germany

scientific article published on 25 May 2020

Presenting Germany's drug pricing rule as a cost-per-QALY rule

artículo científico publicado en 2011

Prioritizing comparative effectiveness research: are drug and implementation trials equally worth funding?

artículo científico publicado en 2011

Prioritizing health services research: an economic perspective

scientific article published on 05 February 2016

Productivity Loss Due to Irritable Bowel Syndrome

artículo científico publicado el 13 de octubre de 2003

Protocol-driven costs in trial-based pharmacoeconomic analyses

artículo científico

Reference pricing and price negotiations for innovative new drugs : viable policies in the long term?

artículo científico publicado en 2013

Sacubitril/Valsartan (LCZ696): A Novel Treatment for Heart Failure and its Estimated Cost Effectiveness, Budget Impact, and Disease Burden Reduction in Germany

artículo científico publicado en 2018

Should Cost-Effectiveness Analysis Include the Cost of Consumption Activities? AN Empirical Investigation

artículo científico publicado en 2015

Simplifying rules for optimal allocation of preventive care resources ⬇️

artículo científico publicado el 1 de abril de 2012

Substantial treatment overuse in the United States?

scientific article published on 01 May 2007

Survivor costs in cost-effectiveness analysis.

artículo científico publicado en 2006

Technology assessment in dentistry: a comparison of the longevity and cost-effectiveness of inlays

artículo científico publicado en 2005

The Clinical and Economic Value of a Successful Shutdown During the SARS-CoV-2 Pandemic in Germany

artículo científico publicado en 2020

The Clinical and Economic Value of a Successful Shutdown During the SARS-CoV-2 Pandemic in Germany

artículo científico publicado en 2020

The German method for setting ceiling prices for drugs: in some cases less data are required

artículo científico publicado en 2011

The additive utility assumption of the QALY model revisited

scientific article published on 11 November 2009

The ethics of non-inferiority trials

The practice-makes-perfect hypothesis in the context of other production concepts in health care

artículo científico publicado en 2003

Theoretical Foundation of Patient v. Population Preferences in Calculating QALYs

artículo científico publicado en 2010

Threshold volumes associated with higher survival in health care: a systematic review

artículo científico publicado en 2003

To treat or not to treat? Cost-effectiveness of ace inhibitors in non-diabetic advanced renal disease - a Dutch perspective

artículo científico publicado en 2013

Trends in rates of orthopedic surgery in Germany: the good, the bad, and the ugly

artículo científico publicado en 2019

Underuse of innovative medicines in Germany: A justification for government intervention?

article

Utilitarian theories reconsidered: common misconceptions, more recent developments, and health policy implications

artículo científico publicado en 2003

Validation of models that estimate the cost-effectiveness of improving patient adherence

artículo científico publicado en 2013

Welfare gains and losses caused by clinical practice guidelines

artículo científico publicado en 2013

What drives US competitiveness in mathematics and science?

When is it worth introducing a quality improvement program? A mathematical model

artículo científico publicado en 2003

When is it worth reducing overuse of health care services? The example of prescribing expensive antihypertensives

artículo científico publicado en 2005

Willingness to pay for new medicines: a step towards narrowing the gap between NICE and IQWiG

artículo científico publicado en 2020

[Cost-effectiveness of quality improvement measures in health care]

scientific article published on 01 August 2002

El valor económico de la tecnología médica.

artículo científico publicado en 2002

Lista de obras de Afschin Gandjour

A 'centres of excellence' approach in health care: points for and against

A model to optimize investments in health technologies, quality of care and research

A model to predict the cost-effectiveness of disease management programs

A model to transfer trial-based pharmacoeconomic analyses to clinical practice

A national hypertension treatment program in Germany and its estimated impact on costs, life expectancy, and cost-effectiveness

A new prize system for drug innovation

A payer's perspective on the cost effectiveness of gastric bypass surgery

A proportional rule for setting reimbursement prices of new drugs and its mathematical consistency

A simulation model to estimate cost-offsets for a disease-management program for chronic kidney disease

A theoretical and empirical investigation into the willingness-to-pay function for new innovative drugs by Germany's health technology assessment agency (IQWiG).

Accounting for increased non-target-disease-specific mortality in decision-analytic screening models for economic evaluation.

Aging diseases - do they prevent preventive health care from saving costs?

An evidence-based disease-management program for patients with diabetic nephropathy.

An evidence-based evaluation of quality and efficiency indicators

Applying GRADE Criteria to Clinical Inputs to Cost-Effectiveness Modeling Studies

Appropriateness of invasive cardiovascular interventions in German hospitals (2000–2001): an evaluation using the RAND appropriateness criteria ⬇️

Assessing the value of a future study

At what time is a reduction of medical under- or overtreatment sensible? Treatment of acute depression as an example

Autonomy, Coercion, and Public Healthcare Guarantees: The Uptake of Sofosbuvir in Germany

Avoiding research waste through cost-effectiveness analysis: the example of medication adherence-enhancing interventions

Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe.

Budgetary Impact and Cost Drivers of Drugs for Rare and Ultrarare Diseases

Burden-of-disease estimates

Capturing disutility from waiting time

Caregiversʼ Quality of Life and Economic Evaluations

Changing the organization of health care

Comment on "Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany".

Comment on: "Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines"

Comment on: "Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation".

Comment on: "Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy"

Comment on: "The Cost Effectiveness of High-Dose Versus Conventional Haemodialysis: A Systematic Review"

Comment on: "The Role of Chronic Disease, Obesity, and Improved Treatment and Detection in Accounting for the Rise in Healthcare Spending Between 1987 and 2011".

Comment on: "impact and cost-effectiveness of a universal strategy to promote physical activity in primary care".

Commentary to: Cost of poor adherence to anti-hypertensive therapy in five European countries

Comparing the validity of different measures of illness severity: a hospital-level analysis for acute myocardial infarction

Considering productivity loss in cost-effectiveness analysis: a new approach

Consumption costs and earnings during added years of life - a reply to Nyman

Convergence of decision rules for value-based pricing of new innovative drugs.

Cost Effectiveness of Secondary vs Tertiary Prevention for Post-Menopausal Osteoporosis

Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany

Cost effectiveness of the German screen-and-treat strategy for postmenopausal osteoporosis

Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women

Cost-Effectiveness Analysis of High-Efficiency Hemodiafiltration Versus Low-Flux Hemodialysis Based on the Canadian Arm of the CONTRAST Study

Cost-Effectiveness of Different Strategies for Selecting and Treating Individuals at Increased Risk of Osteoporosis or Osteopenia: A Systematic Review ⬇️

Cost-effectiveness analysis of different screening procedures for type 2 diabetes: the KORA Survey 2000.

Cost-effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in newly diagnosed type 2 diabetes in Germany

Cost-effectiveness of angiotensin-converting enzyme inhibitors for the prevention of diabetic nephropathy in The Netherlands--a Markov model

Cost-effectiveness of angiotensin-converting enzyme inhibitors in nondiabetic advanced renal disease.

Cost-effectiveness of cardioverter-defibrillators in heart failure patients

Cost-effectiveness of future lockdown policies against the COVID-19 pandemic

Cost-effectiveness of implantable defibrillators after myocardial infarction based on 8-year follow-up data (MADIT II).

Cost-effectiveness of preventing hip fractures by hip protectors in elderly institutionalized residents in Germany

Cost-effectiveness of preventing weight gain and obesity: what we know and what we need to know

Cost-effectiveness of referrals to high-volume hospitals: an analysis based on a probabilistic Markov model for hip fracture surgeries

Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results

Cost-effectiveness of using clinical risk factors with and without DXA for osteoporosis screening in postmenopausal women

Costs and quality in the treatment of acute depression in primary care: a comparison between England, Germany and Switzerland

Costs of dialysis--a regional population-based analysis

Costs of patients with chronic kidney disease in Germany

Defining Comparators According to IQWiG's Efficiency-Frontier Method

Depression and health-related quality of life.

Determining the price for pharmaceuticals in Germany: comparing a shortcut for IQWiG's efficiency frontier method with the price set by the manufacturer for ticagrelor

Direct costs of care in germany for children and adolescents with diabetes mellitus in the early course after onset

Does prevention save costs?

Drug pricing and control of health expenditures: a comparison between a proportional decision rule and a cost-per-QALY rule

Economic analysis of influenza vaccination and treatment

Economic evaluation of Sinfrontal in the treatment of acute maxillary sinusitis in adults

Economic evaluations alongside equivalence and noninferiority trials

Educating authors and reviewers of economic evaluations of health care

Educational epidemiology

Empirical validation of patient versus population preferences in calculating QALYs

Ethical criteria for allocating health-care resources

Ethical objections against including life-extension costs in cost-effectiveness analysis: a consistent approach

European comparison of costs and quality in the treatment of acute back pain

Germany's decision rule for setting ceiling prices of drugs: a comparative analysis with other decision rules

Health care expenditures from living longer--how much do they matter

How much does it cost to change the behavior of health professionals? A mathematical model and an application to academic detailing

Impact of demographic changes on healthcare expenditures and funding in the EU.

Impact of small study bias on cost-effectiveness acceptability curves and value of information analyses